- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05805176
An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms (A-GAMES)
April 18, 2024 updated by: Lumos Labs, Inc.
An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms - A Prospective, Multicenter, Open Label, Single Arm, Intervention Study to Assess Efficacy and Safety of an At-home, Game-based Digital Therapy for Treating Clinical Symptoms of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).
Study Overview
Study Type
Interventional
Enrollment (Estimated)
194
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bob Schafer, PhD
- Phone Number: (530) 746-8565
- Email: bschafer@lumoslabs.com
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Recruiting
- CNS Healthcare of Jacksonville
-
Lakeland, Florida, United States, 33803
- Recruiting
- Accel Clinical Research Sites
-
-
Michigan
-
Rochester Hills, Michigan, United States, 48307
- Recruiting
- Rochester Center for Behavioral Medicine (RCBM)
-
-
Missouri
-
Brentwood, Missouri, United States, 63144
- Recruiting
- Midwest Research Group
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Recruiting
- Hassman Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 22-55 years of age (Cohort I) or 18-21 years of age (Cohort II)
- Confirmed ADHD diagnosis, combined or inattentive type, at Screening based on DSM-5 criteria and established via the MINI-Adult, administered by a trained clinician
- Baseline total score on the DSM 5 Inattentive Symptoms, DSM 5 Hyperactive - Impulsive Symptoms and ADHD Index subscales of the Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) ≥24
- Current, stable use of an FDA approved pharmacological treatment for ADHD for at least 4 weeks prior to screening, but ADHD condition inadequately managed by that medication
- Ability to understand and speak English, follow written and verbal instructions (English), as assessed by the PI and/or Study Coordinator, and give informed consent (English)
- Have ability to connect wireless devices to a functional wireless network daily
- Have access to a computer or smart device (e.g., phone, tablet) with internet access and a Google Chrome web browser
- Ability to comply with all the testing and study requirements
Exclusion Criteria:
- Unstable/uncontrolled, comorbid psychiatric diagnosis, based on clinical interviewing, with significant current active symptoms including but not limited to posttraumatic stress disorder, schizophrenia spectrum and other psychotic disorders, bipolar disorder, autism spectrum disorder, severe obsessive-compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments
- Inadequate IQ to participate in the study as estimated by Investigator (i.e., inability to read/understand the informed consent; inability to understand how the device and therapy (games) work)
- PHQ-9 scores ≥16
- Have previously been assessed by TOVA for potential enrollment in a clinical trial.
- Have previously used a videogame-like digital therapy (e.g., Akili EndeavorRxTM) OR within the last three years, have used a cognitive or brain training platform (e.g., Peak, Brain HQ, Lumosity, Atentiv) for more than two weeks duration
- Known sensitivity to playing video games, such as headaches, dizziness, nausea
- Initiation within the last 4 weeks of behavioral therapy or neurofeedback, or planned initiation during the study. Patients who have been in behavior therapy or neurofeedback consistently for more than 4 weeks may participate provided their routine is unchanged during the course of the study. Patients planning on changing or initiating behavior therapy or neurofeedback during the course of the study will be excluded
- Patient is currently considered a suicide risk in the opinion of the Investigator, as measured by C-SSRS at screening (i.e., score of 4 or 5 on C-SSRS)
- Motor condition (e.g., physical deformity of the hands/arms; protheses) that prevents game playing as observed by the Investigator
- Recent history (within the past 12 months) of suspected alcohol or substance abuse or dependence
- Positive urine drug screen
- History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy
- Visual acuity that cannot be corrected that prevents or negatively impacts game playing as observed by the Investigator
- Any use of psychoactive drugs (other than ADHD medication) that in the opinion of the Investigator may confound study data/assessments
- Has participated in a clinical trial within 90 days prior to screening
- Has a family member or close friend/associate also enrolled/currently participating in the same study
- Any other condition that in the opinion of the Investigator may confound study data/assessments
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ADHD Therapy
|
investigational game-play therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) Inattentive Symptoms subscale
Time Frame: Study Day 0 to Study Day 63
|
The Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) has 66 items with multiple subscales.
|
Study Day 0 to Study Day 63
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adult ADHD Self-Report Scale (ASRS) Inattentive Symptoms Subscale
Time Frame: Study Day 0 to Study Day 63
|
The World Health Organization Adult Self-Report Scale (ASRS) symptom checklist is an 18-item tool to screen for probable ADHD in adults.
The ASRS checklist asks respondents to indicate how they have felt and conducted themselves over the past 6 months in terms of frequency of inattention or hyperactivity symptoms, which are rated from 0 ("never") to 4 ("very often").
The checklist is divided into two parts and results in a "Part A" inattention subscore (range 0-36), a "Part B" hyperactivity/ impulsivity subscore (range 0-36), and a total score based on the full scale (range 0-72).
|
Study Day 0 to Study Day 63
|
Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) ADHD Symptoms Total subscale
Time Frame: Study Day 0 to Study Day 63
|
The Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) has 66 items with multiple subscales.
|
Study Day 0 to Study Day 63
|
Sheehan Disability Scale (SDS)
Time Frame: Study Day 0 to Study Day 63
|
The Sheehan Disability Scale is a five-item, self-rated questionnaire designed to measure the extent to which a patient's disability due to an illness or health problem interferes with work/school, social life/leisure activities, and family life/home responsibilities.
|
Study Day 0 to Study Day 63
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Greg Mattingly, MD, Midwest Research Group
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 15, 2023
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
March 24, 2023
First Submitted That Met QC Criteria
March 28, 2023
First Posted (Actual)
April 7, 2023
Study Record Updates
Last Update Posted (Actual)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 18, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIP-014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
The Hong Kong Polytechnic UniversityRecruiting
-
VIZO Specs LtdRecruiting
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Recruiting
-
Loewenstein HospitalWingate InstituteRecruiting
-
Florida State UniversityRecruiting
-
Florida International UniversityRecruiting
-
Region Örebro CountyRecruiting
-
Johns Hopkins UniversityWithdrawn
-
Tris Pharma, Inc.Premier Research Group plcCompleted
Clinical Trials on ADHD Therapy
-
Lumos Labs, Inc.Completed
-
University of IcelandActive, not recruitingAttention-deficit HyperactivityIceland
-
ArkinFonds NutsOhraCompletedAttention Deficit Hyperactivity Disorder | Substance Use DisordersNetherlands
-
Columbia UniversityCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Northwell HealthThe City College of New YorkRecruiting
-
The University of Hong KongRecruiting
-
Hong Kong Baptist UniversityUniversity Grants Committee, Hong KongCompletedAttention-deficit/Hyperactivity Disorder | Special Education | Attention Deficit Disorder | Special Needs Children | Hyperactivity DisorderHong Kong
-
Göteborg UniversityCompleted
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)CompletedAttention Deficit Disorder With HyperactivityUnited States
-
Children's Hospital Medical Center, CincinnatiTerminated